Precigen (NASDAQ:PGEN) Stock Price Down 4.2% – Time to Sell?

Precigen, Inc. (NASDAQ:PGEN)’s stock price was down 4.2% during trading on Monday . The stock traded as low as $1.73 and last traded at $1.73. Approximately 119,813 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 1,997,533 shares. The stock had previously closed at $1.80.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PGEN shares. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Precigen in a report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Precigen presently has an average rating of “Hold” and an average price target of $7.00.

Precigen Stock Down 6.2 %

The company has a market cap of $489.09 million, a price-to-earnings ratio of -3.04 and a beta of 1.58. The company’s fifty day moving average price is $1.57 and its two-hundred day moving average price is $1.14.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its holdings in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 10,900 shares during the last quarter. Cetera Investment Advisers boosted its holdings in Precigen by 8.9% during the fourth quarter. Cetera Investment Advisers now owns 283,562 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 23,250 shares during the last quarter. Cary Street Partners Financial LLC acquired a new position in Precigen during the fourth quarter worth $98,000. Bank of America Corp DE boosted its holdings in Precigen by 11.6% during the fourth quarter. Bank of America Corp DE now owns 207,300 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 21,626 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Precigen in the fourth quarter valued at $27,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.